Company Overview - Jinkai (Liaoning) Life Science Technology Co., Ltd. is located in Fuxin City, Liaoning Province, and was established on June 8, 2009. The company went public on August 3, 2023. Its main business involves providing small molecule CDMO services to global clients in the life sciences sector, assisting pharmaceutical companies with new drug development projects by offering custom development and production services for small molecule drug intermediates and a limited amount of active pharmaceutical ingredients [2]. Financial Performance - For the period from January to June 2025, Jinkai Life Science achieved operating revenue of 348 million yuan, representing a year-on-year growth of 32.98%. The net profit attributable to the parent company was 71.76 million yuan, showing a significant increase of 123.61% compared to the previous year [2]. Shareholder Information - As of September 19, 2025, the number of shareholders in Jinkai Life Science was 14,300, a decrease of 3.65% from the previous period. The average circulating shares per person increased by 3.78% to 3,968 shares [2]. Financing and Trading Activity - On September 23, Jinkai Life Science's stock price fell by 2.46%, with a trading volume of 105 million yuan. The margin trading data indicated a financing purchase amount of 9.33 million yuan and a repayment of 9.64 million yuan, resulting in a net financing outflow of 308,900 yuan. The total margin balance as of September 23 was 140 million yuan, accounting for 6.91% of the circulating market value, which is above the 80th percentile level over the past year [1]. Dividend Distribution - Since its A-share listing, Jinkai Life Science has distributed a total of 117 million yuan in dividends [3]. Institutional Holdings - As of June 30, 2025, two funds, Yuanxin Yongfeng Ju You A and Yuanxin Yongfeng Xing Yuan A, have exited the list of the top ten circulating shareholders of Jinkai Life Science [3].
金凯生科9月23日获融资买入933.43万元，融资余额1.40亿元